Category Archives: PSK

Autoimmune Disease, Cancer, Clinical Trials, Gastric Cancer, Immunotherapy, Medical Studies, Preventative, PSK

Alternating immunotherapy of advanced gastric carcinoma: A randomized comparison of carbazilquinone and PSK to carbazilquinone in patients with curative gastric resection

A total of 103 patients with advanced gastric carcinoma were randomized after curative surgery to receive an alternate administration of carabzilquinone (CQ) and PSK (Krestin) or carbazilquinone alone.  Each course of therapies started 1 week after the surgical operation and therapy schedules consisted of 9 courses.  In each course of 6 weeks, CQ was administered on day 0, 8, and 15.  In combined immunochemotherapy group, PSK was given orally in 3-divided doses of 2g/m^2/day from the day of the third CQ administration for consecutive 4 weeks.  Estimated survival rate and cumulative survival curve were compared untilizing the data up to 7 years after the operation.  There was no overall significant difference in survival rates between the CQ plus PSK group and the CQ alone group, but a group of patients survived significantly longer when treated with the combination of CQ and PSK.  Neither in more advanced cases nor in cancers of early stages, the addition of PSK provided an additive effect.  The favorable result obtained in one subgroup treated with PSK, suggests that the use of this agent in treating gastric cancers should be carefully evaluated in terms of serosal infiltration and nodal metastasis.?

For full article click here.

News, PSK, PSP

Dr. Yang, Inventor of Coriolus Versicolor PSP extract, Joins inLife as Medical Advisor

Irvine, California (September 15, 2010) inLife, LLC distributors of science-based Health & Wellness products today announced that Professor Q.Y. Yang, inventor of Coriolus versicolor mushroom Polysaccharopeptide (PSP, also commonly called Polysaccharide-peptide) extract, will be on inLife’s Board as Medical Advisor. Dr. Yang is recognized as the world’s foremost expert on Coriolus versicolor research. He is currently the director of the Research Institute of Microbiology & Immunology of Shanghai Teachers University, where he invented the technique of submerged cultivation of mycelia of mushrooms. Dr. Yang is responsible for identifying and isolating the most effective COV-1 strain from over 100 different strains of Coriolus versicolor. In recognition of his invention of PSP and also his outstanding achievements in traditional Chinese medicine, Professor Yang has been recognized with many international honors. Dr. Yang has also received a patent for his discovery of PSP extraction process.

About Coriolus Versicolor

The Coriolus Versicolor mushroom is one of the most widely studied supplements for its immune building properties. Worldwide, there have been over 400 animal and human studies on Coriolus versicolor with over a dozen placebo-based human trials conducted in the west. Traditionally, the Coriolus versicolor mushroom (known as Yun-zhi or cloud mushroom in China) has been used in China for several thousand years because of its immune boosting capabilities. In the 1980s, Dr. Yang conducted further studies and was able to isolate a much more potent strain using a different, alcohol-based extraction process. The result was Polysaccharopeptide or PSP. In the United States, top-ranked hospital and research institutes have reported that Coriolus versicolor helps boost the body’s immune systems with limited side effects and safety of daily oral doses for extended periods of time. In addition, Coriolus versicolor and its potential positive effects has been studied very closely by M.D. Anderson, University of Texas, Loma Linda University, Beth Israel Deaconess Medical Center (a teaching hospital of Harvard Medical School) , The University of San Diego, Sloan-Kettering Center (New York), and Bastyr University (Kenmore, Washington) just to name a few.

inLife Immune Builder with PSP and PSK

inLife offers Coriolus versicolor as a Daily Dietary Supplement in capsule form to help maintain and stimulate the body’s immune system. Coriolus versicolor and its high-potency extracts, PSK and PSP are among the most widely studied supplements for their immune building properties. One would be hard-pressed to find another immune boosting product that has had more research completed or positive comments associated with it. The amount of worldwide comments and studies is compelling. InForce Immune Builder is a proprietary blend of both Polysaccharide-K (PSK) and Polysaccharopeptide (PSP). Both offer much needed immune building assistance and they can be taken on a daily basis. The products are bottled in the United States in an FDA registered bottling facility that is CGMP compliant (Current Good Manufacturing Practices).

About inLife, LLC

Founded in 2007, inLife has been very successful in bringing to market products that have efficacies that are soundly based on scientific research. inLife products are now available in the U.S. as well as the U.K, Canada and Spain. For more information on inForce Immune Builder and the company, please review www.myinlife.com. For further details on inForce, journalists may contact Thomas Kiklas directly at 949-648-2525.

# # #

Founded in 2007, inLife has been very successful in bringing to market products that have efficacies that are soundly based on scientific research. inLife products are now available in the U.S. as well as the U.K, Canada and Spain. For more information on inForce Immune Builder and the company, please review www.myinlife.com. For further details on inForce, journalists may contact Thomas Kiklas directly at 949-648-2525.

Click here to download this press release.

Cancer, Immunotherapy, Medical Studies, PSK

The immunomodulator PSK induces in vitro cytotoxic activity in tumour cell lines via arrest of cell cycle and induction of apoptosis.

Jiménez-Medina E, Berruguilla E, Romero I, Algarra I, Collado A, Garrido F, Garcia-Lora A.

Servicio de Análisis Clínicos e Inmunologia, Hospital Universitario Virgen de las Nieves, Universidad de Granada, Av, de las Fuerzas Armadas 2, 18014 Granada, Spain. evajimenez@fundacionhvn.org

Abstract

BACKGROUND: Protein-bound polysaccharide (PSK) is derived from the CM-101 strain of the fungus Coriolus versicolor and has shown anticancer activity in vitro and in in vivo experimental models and human cancers. Several randomized clinical trials have demonstrated that PSK has great potential in adjuvant cancer therapy, with positive results in the adjuvant treatment of gastric, esophageal, colorectal, breast and lung cancers. These studies have suggested the efficacy of PSK as an immunomodulator of biological responses. The precise molecular mechanisms responsible for its biological activity have yet to be fully elucidated.

METHODS: The in vitro cytotoxic anti-tumour activity of PSK has been evaluated in various tumour cell lines derived from leukaemias, melanomas, fibrosarcomas and cervix, lung, pancreas and gastric cancers. Tumour cell proliferation in vitro was measured by BrdU incorporation and viable cell count. Effect of PSK on human peripheral blood lymphocyte (PBL) proliferation in vitro was also analyzed. Studies of cell cycle and apoptosis were performed in PSK-treated cells.

RESULTS: PSK showed in vitro inhibition of tumour cell proliferation as measured by BrdU incorporation and viable cell count. The inhibition ranged from 22 to 84%. Inhibition mechanisms were identified as cell cycle arrest, with cell accumulation in G0/G1 phase and increase in apoptosis and caspase-3 expression. These results indicate that PSK has a direct cytotoxic activity in vitro, inhibiting tumour cell proliferation. In contrast, PSK shows a synergistic effect with IL-2 that increases PBL proliferation.

CONCLUSION: These results indicate that PSK has cytotoxic activity in vitro on tumour cell lines. This new cytotoxic activity of PSK on tumour cells is independent of its previously described immunomodulatory activity on NK cells.

PMID: 18366723 [PubMed – indexed for MEDLINE]PMCID: PMC2291471Free PMC Article

http://www.ncbi.nlm.nih.gov/pubmed/18366723

Clinical Trials, Immunotherapy, Medical Studies, Melanoma, PSK, PSP

Evaluation of widely consumed botanicals as immunological adjuvants.

1 Comment

Ragupathi G, Yeung KS, Leung PC, Lee M, Lau CB, Vickers A, Hood C, Deng G, Cheung NK, Cassileth B, Livingston P.

Laboratory of Tumor Vaccinology, Melanoma and Sarcoma Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, United States. ragupatg@mskcc.org

Abstract

BACKGROUND: Many widely used botanical medicines are claimed to be immune enhancers. Clear evidence of augmentation of immune responses in vivo is lacking in most cases. To select botanicals for further study based on immune enhancing activity, we study them here mixed with antigen and injected subcutaneously (s.c.). Globo H and GD3 are cell surface carbohydrates expressed on glycolipids or glycoproteins on the cell surface of many cancers. When conjugated to keyhole limpet hemocyanin (KLH), mixed with an immunological adjuvant and administered s.c. the magnitude of the antibody responses against globo H, GD3 and KLH depend largely on the potency of the adjuvant. We describe here the results obtained using this s.c. immunization model with seven botanicals purported to have immune stimulant effects.

METHODS: Groups of 5-10 mice were immunized with globo H-KLH or GD3-KLH mixed with botanical, saline or positive control immunological adjuvant, s.c. three times at 1 week intervals. Antibody responses were measured 1 and 2 weeks after the 3rd immunization. The following seven botanicals and fractions were tested: (1) H-48 (Honso USA Co.), (2) Coriolus versicolor raw water extract, purified polysaccharide-K (PSK) or purified polysaccharide-peptide (PSP) (Institute of Chinese Medicine (ICM)), (3) Maitake extract (Yukiguni Maitake Co. Ltd. and Tradeworks Group), (4) Echinacea lipophilic, neutral and acidic extracts (Gaia Herbs), (5) Astragalus water, 50% or 95% ethanol extracts (ICM), (6) Turmeric supercritical (SC) or hydro-ethanolic (HE) extracts (New Chapter) or 60% ethanol extract (ICM) and (7) yeast beta-glucan (Biotec Pharmacon). Purified saponin extract QS-21 (Antigenics) and semisynthetic saponin GPI-0100 (Advanced BioTherapies) were used as positive control adjuvants. Sera were analyzed by ELISA against synthetic globo H ceramide or GD3 and KLH.

RESULTS: Consistent significant adjuvant activity was observed after s.c. vaccination with the Coriolus extracts (especially PSK), a 95% ethanol extract of Astragalus and yeast beta-glucan, and (to a lesser extent) Maitake. Antibodies against KLH in all cases and against globo H in most cases were induced by these botanicals. Little or no adjuvant activity was demonstrated with H-48 or Echinacea extracts or the Astragalus water extract. Experiments with GD3-KLH as immunogen confirmed the adjuvant activity of the Coriolus, yeast beta-glucan and Astragalus extracts. While extraction with ethanol concentrated the active ingredients in Astragalus, it had no impact on Coriolus where the 90% ethanol precipitate and solute were equally active.

CONCLUSIONS: Some, but not all, botanicals purported to be immune stimulants had adjuvant activity in our model. PSK and Astragalus were surprisingly active and are being further fractionated to identify the most active adjuvant components.

PMID: 18640165 [PubMed – indexed for MEDLINE]PMCID: PMC2565601

http://www.ncbi.nlm.nih.gov/pubmed/18640165

PSK, PSP, Types Of Extract

Production and structural analysis of the polysaccharide secreted by Trametes (Coriolus) versicolor ATCC 200801.

Rau U, Kuenz A, Wray V, Nimtz M, Wrenger J, Cicek H.

Institute of Biochemistry and Biotechnology, Technical University Braunschweig, Spielmannstr. 7, 38106 Braunschweig, Germany. U.Rau@tu-bs.de

Abstract

Trametes versicolor ATCC 200801 secretes 4.1 g L(-1) of exopolysaccharide (EPS) when synthetic minimal medium and low-shear bioreactor cultivation technique are used. Structural and compositional analyses by thin layer chromatography, gas chromatography-mass spectrometry, electrospray ionization tandem mass spectrometry, and nuclear magnetic resonance spectroscopy yielded predominantly glucose and small amounts of galactose, mannose, arabinose, and xylose. The main EPS is composed of beta-1,3/beta-1,6-linked D-glucose molecules which is identical with Schizophyllan but does not possess a triple helical arrangement as secondary structure. Two molar mass fractions were detected by size exclusion chromatography yielding weight-average molecular weights of 4,100 and 2.6 kDa. Protein content varies between 2-3.6% (w/w). The exopolysaccharide is different in the nature of the glycosidic linkage, composition of monosaccharides, protein content, and weight-average molecular weight compared to the well-known polysaccharopeptide (PSP) and polysaccharopeptide Krestin (PSK).

PMID: 18800181 [PubMed – indexed for MEDLINE]

http://www.ncbi.nlm.nih.gov/pubmed/18800181

Cancer, Immunotherapy, Medical Studies, PSK

Protein-bound polysaccharide-K (PSK) directly enhanced IgM production in the human B cell line BALL-1

Maruyama S, Akasaka T, Yamada K, Tachibana H.

Laboratory of Food Chemistry, Division of Applied Biological Chemistry, Department of Bioscience and Biotechnology, Faculty of Agriculture, Kyushu University, Higashi-ku, Fukuoka, Japan. marushins2003@ybb.ne.jp

Abstract

Protein-bound polysaccharide-K (PSK) prepared from the basidiomycete Coriolus versicolor has been used as a biological response modifier for the treatment of cancer patients. Many studies describing the immunomodulatory effects and direct anti-cancer effects of PSK have been reported. Most of studies describing the immunomodulatory effects focused on cellular immunity, although there were several studies which focused on humoral immunity where PSK was shown to be able to induce antibody production in vivo. However, even in these humoral immunity studies, it is thought that the enhancement of antibody production was due to the activation of cellular immunity. In this study, we investigated the direct effect of PSK on B cells and discovered that PSK was able to enhance IgM production in the human B cell line BALL-1. Furthermore, BALL-1 was shown to have the characteristic features of B-1a cells, which are independently involved in the primary immune response. These results show that there is a possibility that PSK directly acts on B cells and simultaneously enhances both humoral immunity and cellular immunity.

PMID: 18848763 [PubMed – indexed for MEDLINE]

http://www.ncbi.nlm.nih.gov/pubmed/18848763

Cancer, Clinical Trials, Gastric Cancer, Immunotherapy, Medical Studies, PSK

Alternating immunochemotherapy of advanced gastric carcinoma: a randomized comparison of carbazilquinone and PSK to carbazilquinone in patients with curative gastric resection.

A total of 103 patients with advanced gastric carcinoma were randomized after curative surgery to receive an alternate administration of carbazilquinone (CQ) and PSK (Krestin) or carbazilquinone alone. Each course of therapies started 1 week after the surgical operation and therapy schedules consisted of 9 courses. In each course of 6 weeks, CQ (2 mg/m2/week) was administered on day 0, 8, and 15. In combined immunochemotherapy group, PSK was given orally in 3-divided doses of 2 g/m2/day from the day of the third CQ administration for consecutive 4 weeks. Estimated survival rate and cumulative survival curve were compared utilizing the data up to 7 years after the operation. There was no overall significant difference in survival rates between the CQ plus PSK group and the CQ alone group, but a group of patients whose disease was classified as S1 + S2(N1-2) survived significantly longer when treated with the combination of CQ and PSK. Neither in more advanced cases (greater than S3 or greater than N3) nor in cancers of early stages, the addition of PSK provided an additive effect. The favorable result obtained in one subgroup treated with PSK, suggests that the use of this agent in treating gastric cancers should be carefully evaluated in terms of serosal infiltration and nodal metastasis.

Clinical Trials, Colorectal Cancer, Immunotherapy, Medical Studies, PSK

Adjuvant therapy with protein-bound polysaccharide K and tegafur uracil in patients with stage II or III colorectal cancer: randomized, controlled trial.

PURPOSE: Intravenous fluorouracil and leucovorin for six to eight months is currently a standard adjuvant treatment for Stage III colon cancer; however, this regimen is complex, inconvenient, and has a high intolerability. Adjuvant chemotherapies are claimed for objective response rates with an acceptable safety profile and complexity. We investigated the benefits of oral protein-bound polysaccharide K added to oral tegafur/uracil on curatively resected Stage II or III colorectal cancer. METHODS: We prospectively randomized 207 patients to treatments of either oral 3.0 g protein-bound polysaccharide K plus 300 mg tegafur/uracil or 300 mg tegafur/uracil alone for two years following 12 mg/m2 and 8 mg/m2 mitomycin treatment on postoperative Days 1 and 2, respectively. The primary end points were disease-free and overall survival, and recurrence rates. RESULTS: Three (1.4 percent) patients were declared ineligible, and three patients did not start treatment. In total, 201 patients were analyzed. The three-year, disease-free survival rate was 80.6 percent (standard error = 3.4 percent) in the protein-bound polysaccharide K group (P = 0.02) compared with 68.7 percent (SE = 5.7 percent) in the control group after a median follow-up of 3.7 years. The estimated relative risk of recurrence in the control group was 1.87 (95 percent confidence interval, 1.10-3.20) at three years. The three-year, overall survival rate was 87.3 percent (standard error = 2.9 percent) in the protein-bound polysaccharide K group and 80.6 percent (standard error = 4.8 percent) in the control group (P = 0.24). The three-year, overall survival rate in 80 pathological TNM Stage III patients was 83.0 percent (standard error = 5.2 percent) in the protein-bound polysaccharide K group and 59.3 percent (standard error = 9.5 percent) in the control group (P = 0.02). Protein-bound polysaccharide K prevented distant metastases (P = 0.05), particularly lung metastases (P = 0.01). The incidence of adverse effects was minimal, and compliance was good. CONCLUSION: Adjuvant therapy using a combination of oral protein-bound polysaccharide K and tegafur/uracil is highly effective in preventing the recurrence of colorectal cancer in Stage II or III patients, and increases overall survival in pathological TNM Stage III. These results will be a sufficient proof to conduct a larger study to compare tegafur/uracil/protein-bound polysaccharide K with 5-fluorouracil/leucovorin.

Immunotherapy, News, PSK, PSP

Introducing inForce Immune Builder

Irvine, California (September 7, 2010) inLife, LLC, distributors of science-based Health & Wellness products, today introduced inForce Immune Builder, a new product that clinical research shows helps stimulate the body’s immune system. inForce’s main ingredient, the Coriolus versicolor mushroom mycelia extract, is one of the most widely studied supplements for its immune building properties and is now available to the public and the direct-selling industry. Worldwide, there have been over 400 animal and human studies on Coriolus versicolor, with over a dozen placebo-based human trials conducted in the west.

inLife Immune Builder with PSP and PSK
inLife offers Coriolus versicolor as a Daily Dietary Supplement in vegan capsule form to help maintain and stimulate the body’s immune system. Coriolus versicolor, PSK and PSP are among the most widely studied supplements for their immune building properties. One would be hard pressed to find another immune boosting product that has had more research completed or positive comments associated with it. The amount of worldwide comments and studies is compelling. inForce Immune Builder is a proprietary blend of both Polysaccharide-K (PSK) and Polysaccharide Peptide (PSP). Both offer much-needed immune building assistance and they can be taken on a daily basis. The products are bottled in the United States in an FDA-registered bottling facility that is cGMP compliant (Current Good Manufacturing Practices).

Hospital and Research Institutes Report on Coriolus Versicolor
In the United States, top-ranked hospital and research institutes have reported that “Coriolus versicolor, PSK and PSP help boost the body’s immune system with limited side effects and safety of daily oral doses for extended periods of time.” In addition, Coriolus versicolor and its potential positive effects has been studied very closely by M.D. Anderson, University of Texas, Loma Linda University, Beth Israel Deaconess Medical Center (a teaching hospital of Harvard Medical School) , The University of San Diego, Sloan-Kettering Center (New York), and Bastyr University (Kenmore, Washington), just to name a few.

About inLife, LLC
Founded in 2007, inLife has been very successful in bringing to the market products that have efficacies that are soundly based on scientific research. inLife products are now available in the U.S. as well as the U.K, Canada and Spain. For more information on inForce Immune Builder and the company, please review www.myinlife.com. For further details on inForce, journalists may contact Thomas Kiklas directly at 949-648-2525.

# # #

Founded in 2007, inLife has been very successful in bringing to the market products that have efficacies that are soundly based on scientific research. inLife products are now available in the U.S. as well as the U.K, Canada and Spain.

Click here to download this press release.

Breast Cancer, Cancer, Cervical Cancer, Colorectal Cancer, Esophageal Cancer, Gastric Cancer, Human Papillomavirus (HPV), Immunotherapy, Lung Cancer, Lymphocytes, Medical Studies, News, PSK, PSP

Coriolus Versicolor is Potent Mushroom for Fighting Cancer and Autoimmune Diseases – By: Barbara L. Minton, citizen journalist

(NaturalNews – January 28, 2009) For thousands of years Chinese medicine has prized the mushroom for its energizing and healing properties. Chinese legend is filled with stories of those who discovered the 1,000 year old mushroom and became immortal. In the West, acceptance is based less on tradition and more on the results of the scientific method. Researchers have been busy scientifically documenting what Chinese tradition dictates, that mushrooms are some of the most potent medicines on the plant. Recent research findings have shown the Coriolus versicolor mushroom stands out above the rest for regulating the immune system.

Coriolus versicolor found to be effective against cancer and human papillomavirus

Researchers at the Sloan-Kettering Cancer Center in New York tested several botanicals for their immune enhancing activity using a subcutaneous immunization model of cell surface carbohydrate expression in cancer cells in a study published in September, 2008 Vaccine. They found Coriolus versicolor to display consistent and significant immune enhancement activity superior to all other coumpounds tested. The superiority of Coriolus to yeast beta-glucan, maitake, turmeric, echinacea, and preparation H-48 from Honso USA, was described as surprising. Although the exhibited levels of immune enhancing ability of astragalus was also impressive, it was surpassed by that of Coriolus.

The March, 2008 BMC Cancer reports Coriolus versicolor has shown anticancer activity with positive results in the treatment of gastric, esophageal, colorectal, breast and lung cancers. The efficacy of its protein-bound polysaccharide as an immunomodulator is credited. This activity was independent of its previously described immunomodulatory effect on NK cells.

The journal Cancer Immunology and Immunotherapy reports double blind trials on 111 patients with colorectal cancer, using Coriolus versicolor. Although traditional medicine offers little help for colon cancer patients, Coriolus showed a remarkable enhancement of the patient’s white blood cells, even in advanced colon cancer cases. The white cells greatly increased natural chemotactic motion and phagocytosis, the ability to scavenge toxins and kill pathogens. Coriolus was also used with patients as a helpful maintenance therapy following cancer surgery.

The results of a year long clinical trial examining the effects of mushroom supplementation in patients with Human Papillomavirus (HPV) were so impressive they were presented in 2008 at the 20th European Congress of Obstetrics and Gynocology. Dr. Silva Couto and his research team found that Coriolus versicolor supplementation over the period of one year substantially increased regression of dysplasia and induced clearance of the high-risk subtypes of the HPV responsible for cervical cancer. Coriolus supplementation demonstrated a 72 percent regression rate in lesions compared to 47.5 percent without supplementation, and a 90 percent regression rate in the high risk HPV virus sub-types compared to 8.5 percent without.

After using the supplement for one year, 72.5 percent of recipients reverted to normal cytology compared with only 47.5 percent of the control group. Coriolus supplementation produced a 90 percent regression rate in the high risk HPV virus sub-tupes compared to an 8.5 percent regression without supplementation.

It is also likely that Coriolus versicolor would be beneficial in high-grade squamous intraepithelial lesion (HSIL), a precancerous condition in which the cells of the uterine cervix are moderately or severely abnormal. The lead physician of the study noted that the optimal supplementation period may be as short as six months.

Coriolus versicolor modulates autoimmune diseases

T cells belong to a group of while blood cells known as lymphocytes, and play a central role in cell-mediated immunity. The activation of T helper (Th) cell subsets also plays an important role in immunity. Uncontrolled Th responses lead to autoimmune and inflammatory diseases. The identification of agents that modulate these helper cells is essential for controlling autoimmune diseases. A study from the November, 2008 Journal of Pharmacy and Pharmacology, reported that polysaccharopeptide (PSP) from Coriolus versicolor exhibited the ability to control aberrant T lymphocyte activation through ciclosporin-like activity. PSP alone suppress production of activated T cells.

What makes Coriolus versicolor special?

Coriolus versicolor, also referred to as the turkey-tail mushroom, contains large quantities of Beta-glucans that act to stimulate the immune system. Coriolus can dramatically regenerate and rejuvenate the body. Its most active medicinal components are biological response modifiers called protein-bound polysaccharides. These polysaccharides are known as Krestin or PSK in Japan, and as Yun zhi, or PSP in China. There have been reports of cases of Bell’s palsy clearing up with use of Coriolus for just a few days. Others have found it effective against bronchitis.

Other studies have shown that Coriolus can double the number of natural killer cells after only 8 weeks of treatment. Coriolus has also been found to help patients with chronic fatigue syndrome and may be an effective treatment for Lyme disease.

More research documents the anti-tumor benefits of Coriolus

Japanese researchers screened 200 of the best phytochemicals (plant extracts) known for anti-tumor activity. Coriolus versicolor was designated as exhibiting the greatest amount of anti-tumor activity. In another Japanese study, 185 people with lung cancer at different stages were given radiation. Doctors found those who also took Coriolus showed the best tumor shrinkage and the best survival rate. Another study involving stomach cancer patients produced similar results. Those who received Coriolus survived significantly longer, felt better and had fewer side effects.

Coriolus is first line defense against infection

Coriolus is a good centerpiece for your natural medicine chest, even if you are currently the picture of health. When any type of infection strikes, you will be ready. Coriolus can be used to target any infected organ, gland or tissue. Its immune enhancing properties provide an increased response to deal effectively with infections, and do this without over stimulating the immune system.

Sources:

Clinical Trial Results Show Proof of Concept for Use of Coriolus Versicolor As Immunonutrition in IPV Patients With Cervical Lesions, Medical News Today.

Coriolus, www.cocoonnutrition.org.

Coriolus Versicolor, University of California, San Diego Complementary and Alternative Therapies for Cancer Patients.

About the author

Barbara is a school psychologist, a published author in the area of personal finance, a breast cancer survivor using “alternative” treatments, a born existentialist, and a student of nature and all things natural.

Source: NaturalNews – http://www.naturalnews.com/025455.html